Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare cancers and viral infections. This dedicated news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access real-time information about Chimerix's innovative pipeline, including its lead candidate dordaviprone for H3 K27M-mutant glioma and ongoing research in antiviral treatments. The curated collection features press releases, financial reports, and scientific presentations – all vital for understanding the company's progress in addressing unmet medical needs.
Key content categories include clinical trial results, FDA communications, partnership announcements, and financial performance updates. Each update is carefully verified to ensure accuracy and relevance for stakeholders monitoring therapeutic advancements in oncology and infectious diseases.
Bookmark this page for streamlined access to Chimerix's latest developments. Check regularly for critical updates on drug approvals, research breakthroughs, and strategic initiatives that shape the company's trajectory in biopharmaceutical innovation.
Chimerix (NASDAQ: CMRX) announced inducement grants to two new employees under Nasdaq Listing Rule 5635(c)(4) on July 5, 2024. The grants, approved by the Compensation Committee on July 1, 2024, include non-statutory stock options to purchase a total of 120,000 shares of common stock. The stock options have an exercise price equivalent to the closing trading price as of the grant date, a 10-year term, and vest over four years. This includes one-fourth vesting on the first-year anniversary of the hire and the remainder vesting monthly over the next three years. The options are subject to the 2024 Equity Incentive Plan's terms, although granted outside of it. Chimerix focuses on developing medicines for life-threatening diseases, with its leading program, ONC201, targeting H3 K27M-mutant glioma.
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, announced that CEO Mike Andriole will join a fireside chat at the Jefferies Global Healthcare Conference.
The event is scheduled for June 6, 2024, at 3:00 p.m. ET. An audio webcast will be available on Chimerix's Investor Relations website and archived for 90 days.
Chimerix reported its First Quarter 2024 Financial Results and Operational Update, highlighting the progress of the Dordaviprone (ONC201) ACTION study and the encouraging Phase 1 results of ONC206. The company aims to bring dordaviprone to patients facing H3 K27M-mutant diffuse glioma sooner, focusing on regulatory interactions and provisional registrations for accelerated approval. Chimerix also disclosed a net loss of $21.9 million for Q1 2024, with research and development expenses remaining stable. The company's balance sheet indicates $188.2 million in capital for operations with no outstanding debt.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
